144 related articles for article (PubMed ID: 12099646)
1. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Eur J Surg Oncol; 2002 Jun; 28(4):383-7. PubMed ID: 12099646
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Breast Cancer; 2002; 9(2):111-7. PubMed ID: 12016390
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factors on the Positivity for Metastases of the Axillary Lymph Nodes from Primary Breast Cancer.
Kondov B; Kondov G; Spirovski Z; Milenkovikj Z; Colanceski R; Petrusevska G; Pesevska M
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):81-90. PubMed ID: 28593885
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Her-2, EGFR and cyclin D1 in primary breast cancer and paired metastatic lymph nodes: an immunohistochemical and chromogenic in situ hybridization study.
Cho EY; Han JJ; Choi YL; Kim KM; Oh YL
J Korean Med Sci; 2008 Dec; 23(6):1053-61. PubMed ID: 19119452
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of p53, c-erbB-2 and epidermal growth factor receptor on head and neck carcinoma.
Parise Junior O; Carvalho LV; Miguel RE; Kowalski LP
Sao Paulo Med J; 2004 Nov; 122(6):264-8. PubMed ID: 15692721
[TBL] [Abstract][Full Text] [Related]
6. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.
Reed W; Hannisdal E; Boehler PJ; Gundersen S; Host H; Marthin J
Cancer; 2000 Feb; 88(4):804-13. PubMed ID: 10679650
[TBL] [Abstract][Full Text] [Related]
8. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.
Horita K; Yamaguchi A; Hirose K; Ishida M; Noriki S; Imamura Y; Fukuda M
Eur J Histochem; 2001; 45(1):73-84. PubMed ID: 11411868
[TBL] [Abstract][Full Text] [Related]
10. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues.
Shimizu C; Fukutomi T; Tsuda H; Akashi-Tanaka S; Watanabe T; Nanasawa T; Sugihara K
J Surg Oncol; 2000 Jan; 73(1):17-20. PubMed ID: 10649273
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
12. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.
Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997
[TBL] [Abstract][Full Text] [Related]
13. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer.
O'Malley FP; Saad Z; Kerkvliet N; Doig G; Stitt L; Ainsworth P; Hundal H; Chambers AF; Turnbull DI; Bramwell V
Hum Pathol; 1996 Sep; 27(9):955-63. PubMed ID: 8816892
[TBL] [Abstract][Full Text] [Related]
14. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival.
Reinartz JJ; George E; Lindgren BR; Niehans GA
Hum Pathol; 1994 Oct; 25(10):1075-83. PubMed ID: 7927313
[TBL] [Abstract][Full Text] [Related]
15. Micrometastatic p53-positive cells in the lymph nodes of early stage epithelial ovarian cancer: prognostic significance.
Suzuki M; Ohwada M; Saga Y; Kohno T; Takei Y; Sato I
Oncology; 2001; 60(2):170-5. PubMed ID: 11244333
[TBL] [Abstract][Full Text] [Related]
16. Differential Expression of RAGE, EGFR and Ki-67 in Primary Tumors and Lymph Node Deposits of Breast Carcinoma.
Aboushousha T; Hammam O; Safwat G; Eesa A; Ahmed S; Esmat ME; Helmy AH
Asian Pac J Cancer Prev; 2018 Aug; 19(8):2269-2277. PubMed ID: 30139236
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ER, PR and HER-2/neu (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer.
Azizun-Nisa ; Bhurgri Y; Raza F; Kayani N
Asian Pac J Cancer Prev; 2008; 9(4):553-6. PubMed ID: 19256737
[TBL] [Abstract][Full Text] [Related]
18. Age-associated biomarker profiles of human breast cancer.
Eppenberger-Castori S; Moore DH; Thor AD; Edgerton SM; Kueng W; Eppenberger U; Benz CC
Int J Biochem Cell Biol; 2002 Nov; 34(11):1318-30. PubMed ID: 12200028
[TBL] [Abstract][Full Text] [Related]
19. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
20. Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study.
Toi M; Tominaga T; Osaki A; Toge T
Breast Cancer Res Treat; 1994 Jan; 29(1):51-8. PubMed ID: 7912567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
